Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados

Topics

Temas

Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
Figuras y tablas -
Figure 1

Methodological quality summary: review authors' judgements about each methodological quality item for each included study.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Study

Outcome

definition

Treatment arm

Control arm

P value

All patients

Bisogno 2009

3‐years PFS

N=62

35.3% (95% CI: 24‐47%)

NA

NA

Bisogno 2009

3‐years OS

42.3% (95% CI: 31‐54%)

NA

NA

Bisogno 2009

Toxic death

3

NA

NA

Carli 1999

5‐years EFS

N=52

29% (95%CI: 16‐41%)

N=44

23% (95%CI: 11‐36%)

0.3

Carli 1999

5‐years OS

36% (95%CI: 16‐41%)

27% (95%CI: 14‐41%)

0.2

Carli 1999

Toxic death

1

1

NA

Klingebiel 2008

5‐years EFS

Not reported

Not reported

Not reported

Klingebiel 2008

5‐years OS

N=34

15% (95%CI: 3‐27%)

N=40

52% (95%CI: 34‐68%)

<0.01

Klingebiel 2008

Toxic death

1

0

NA

Patients without bone or BM disease

Klingebiel 2008

5‐years OS

N=20

40% (95%CI: 19‐61%)

n=31

73% (95%CI: 57‐89%)

0.04

Klingebiel 2008

Klingebiel 2008

High‐risk patients with BM and/or bone involvement

Klingebiel 2008

5‐years OS

N=24

13% (95%CI: 1‐25%)

N=19

17% (95%CI: 1‐33%)

0.75

Klingebiel 2008

Klingebiel 2008

Figuras y tablas -
Analysis 1.1

Comparison 1 High‐dose chemotherapy and stem cell rescue versus standard‐dose chemotherapy, Outcome 1 Event‐free survival (EFS), overall survival (OS) and adverse effects.

Ir a la figura de la revisión
Table 1. External validity study/control group, intervention, follow up and outcome

Klingebiel 2008

Carli 1999

Bisogno 2009

Study group well described:

Description of age, number of metastatic sites, bone/bone marrow metastases, primary tumour localisation

+ = 3 or 4 items; ≈ = 2 items; ‐ = 0 or 1 item

+

+

+

Control group well described:

Description of age, number of metastatic sites, bone/bone marrow metastases, primary tumour localisation

+ = 3 items; ≈ = 2 items; ‐ = 0 or 1 item

+

+

No control group

Study group intervention well described:

Type of chemotherapy, dosage, local treatment, type of transplant

+ = 3 or 4 items; ≈ = 2 items; ‐ = 0 or 1 item

+

+

+

Control group intervention well described:

Type of chemotherapy, dosage, local treatment

+ = 3 items; ≈ = 2 items; ‐ = 0 or 1 item

≈

+

No control group

Follow up well described:

Minimal follow up described = +

Minimal follow up not described = ‐

+

+

+

Outcome well described:

Outcome measurement well described (EFS/OS/toxicity) = +

Outcome measurement not well described (EFS/OS/toxicity) = ‐

‐

+

+

EFS: event‐free survival
OS: overall survival

Figuras y tablas -
Table 1. External validity study/control group, intervention, follow up and outcome
Ir a la tabla de la revisión
Comparison 1. High‐dose chemotherapy and stem cell rescue versus standard‐dose chemotherapy

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Event‐free survival (EFS), overall survival (OS) and adverse effects Show forest plot

Other data

No numeric data

1.1 All patients

Other data

No numeric data

1.2 Patients without bone or BM disease

Other data

No numeric data

1.3 High‐risk patients with BM and/or bone involvement

Other data

No numeric data
Figuras y tablas -
Comparison 1. High‐dose chemotherapy and stem cell rescue versus standard‐dose chemotherapy
Ir a la tabla de la revisión